Immuron Limited (AU:IMC)
ASX:IMC
Want to see AU:IMC full AI Analyst Report?
IMC Stock Chart & Stats
AU$0.04
<AU$0.01(3.80%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(3.80%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume128.40K
Average Volume (3M)862.36K
Market Cap
AU$9.47M
Enterprise Value-AU$2.52M
Total Cash (Recent Filing)AU$10.00M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding326,653,600
10 Day Avg. Volume372,599
30 Day Avg. Volume862,359
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.42M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA very low debt-to-equity ratio reduces interest burden and preserves financial flexibility. For a biotech with costly trials and commercialization steps, minimal leverage improves the company's ability to weather funding cycles, supports strategic partnering, and limits fixed obligations over the next 2-6 months and beyond.
Consistent Revenue GrowthPositive top-line growth demonstrates commercial traction for its products or early market adoption. Sustained revenue increases provide a foundation to scale operations, justify continued investment in the pipeline, and strengthen negotiating leverage with distributors or partners over the medium term.
Specialized Oral Antibody PlatformA differentiated platform targeting GI and infectious-disease indications creates a durable competitive niche. Oral, colostrum-derived antibodies are a specialized offering with potential repeat-use products and partner interest, supporting longer-term commercialization routes and licensing opportunities across multiple indications.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operational and free cash flows erode financial runway and force reliance on external funding or dilutive capital raises. This constrains investments in trials, manufacturing scale-up, and commercialization efforts, elevating execution and financing risk over the coming months.
Unprofitable With Negative MarginsNegative net profit and EBIT margins indicate the business has yet to achieve sustainable unit economics. Without margin improvement through scale, cost control, or higher-margin revenue, generating positive free cash flow and funding ongoing R&D will remain challenging, pressuring long-term viability.
Very Small Operational ScaleA tiny employee base limits internal capacity for R&D, regulatory, commercial and manufacturing functions, increasing dependence on external partners and vendors. That reliance can slow program timelines, add coordination risk, and reduce control over costs and execution during critical development/commercial phases.
Immuron Limited News
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is AU$9.47M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 28, 2026 which is in 110 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.007.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -AU$0.007 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMC Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.20%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
18.12%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Avecho Biotechnology Limited
―
Anatara Lifesciences Ltd
―
Argenica Therapeutics Ltd
―
EZZ Life Science Holdings Ltd.
―
Biome Australia Ltd
―